The Gingival Fibromatoses by Sofia Douzgou & Bruno Dallapiccola
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
The Gingival Fibromatoses 
Sofia Douzgou1 and Bruno Dallapiccola2 
1Department of Genetics, Institute of Child Health 
“Aghia Sophia” Children’s Hospital, Athens 
2Division of Medical Genetics, “Bambino Gesù” Pediatric Hospital IRCCS, Rome 
1Greece 
2Italy 
1. Introduction  
1.1 Definition 
Gingival fibromatosis (GF) is a slowly progressive, benign, non-bleeding, painless, localized 
or generalized overgrowth of the maxillary and mandibular keratinized gingiva (Baptista, 
2002). It is also recognized as congenital hypertrophy of the gums, gingivae elephantiasis, 
gingival gigantism, symmetrical fibroma of the palate, gingival hyperplasia, gingival 
overgrowth (GO), and congenital macrogengiva (Emerson, 1965). The condition occurs both 
in isolated and syndromic forms, and results from either genetic or acquired mechanisms. 
The most common causes accounting for the isolated forms include the effect of a systemic 
drug treatment and single gene mutations (hereditary GF or HGF). In addition GF can 
manifest within a systemic disease (Häkkinen and Csiszar, 2007). 
1.2 Clinical presentation 
Gingival overgrowth’s dimensions are classified in three grades: grade I: growth confined to 
the interdental papilla, grade II: growth involving both papilla and marginal gingiva, grade 
III: growth which covers three quarters or more of the dental crown (Bökenkamp et al., 
1994). In referral to the period of onset, the overgrowth can be classified as: pre-eruptive (<6 
months of age), during the deciduous dentition (from 6 months to 6 years), during the 
mixed dentition period (6 to 12 years) and during the permanent dentition periods, before 
(12 to 20 years) and after adolescence (age 20 or later). The overgrowth results in dental 
defects, including diastemata, malocclusion, delayed eruption of permanent dentition or 
prolonged retention of primary dentition, causing aesthetic and functional problems. 
Treatment with functional gingivectomy is often followed by recurrence of the overgrowth. 
Given the rarity of HGF, available information about its clinical presentation is based on 
individual observations. The phenotypic spectrum is considerably wide and varies both for 
the number of teeth involved and the degree of clinical expression. The localized forms of 
HGF usually involve the maxillary tuberosities and labial gingiva around the mandibular 
molars. However, the symmetric, generalized form of HGF, involving the labial, lingual and 
palatal gingiva is the most common. Males and females are equally affected. Hyperplastic 
gums may be normal or erythematous and consist of dense, fibrous tissue that feels fixed 
and nodular on palpation. Although the alveolar bone is not usually involved, gingival 
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hyperplasia causes periodontal problems because of difficult oral hygiene. The overgrowth 
can also result in functional and aesthetic problems, create diastemata, prevent or slow the 
growth of teeth and determine facial changes as a result of lip protrusion. The overgrowth 
can also lead to serious speech and chewing problems and may prevent the normal closure 
of the lips (Baptista, 2002). 
The onset of GO usually coincides with the eruption of the permanent incisors, or, 
sometimes, with the eruption of primary dentition. In very rare cases, it can also be 
congenital (Anderson et al., 1969). Since HGF has never been observed in edentulous 
patients, it seems that the presence of dentition is necessary for the development of GO. 
1.3 Histology 
Histological characterization and differentiation has not been possible, to date, for all forms 
of HGF, especially for the syndromic ones. The various forms of HGF have similar 
histological features, suggesting that the pathogenic mutations affect different levels of the 
same cellular or molecular pathway. Hereditary gingival fibromatosis is characterized by 
moderate hyperplasia of the hyperkeratotic epithelium, comprised a network of elongated 
ridges. The epithelial hyperplasia may also be secondary to acanthosis, which has, however, 
only been found in areas of chronic inflammation. Fibrosis occurs with accumulation of 
collagen and elastic and oxytalan fibers in the connective tissue, comprised a few fibroblasts 
and blood vessels. Fibroblasts seem to alternate with thin or thick collagen fibrils. Unlike the 
characteristic "woven basket" arrangement of collagen fibers in the normal gingiva, the ones 
of fibrotic gingiva appear parallel. Rarely, osseous calcifications may be present as well as 
many neurovascular bundles (Kelekis-Cholakis et al., 2002, Doufexi et al., 2005). 
The diagnosis of HGF is based on the collection of clinical history and on clinical 
examination, since no specific immunohistochemical markers have been identified, to date. 
2. Isolated gingival fibromatosis 
2.1 Drug-induced gingival fibromatosis 
The most common cause of isolated GO involves anticonvulsant drug therapy, the use of 
calcium channel blockers for treating angina and hypertension or cyclosporine A for 
preventing the rejection of organs transplanted in subjects affected by autoimmune diseases. 
 
Anticonvulsants Calcium channel blockers Antibiotics 
Phenytoin Nifedipine Cyclosporin A 
Carbamazepine Amlodipine  
Etosuximide Bepridil  
Sodium valproate Felodipine  
Primidone Nitrendipine  
Fenoprofen Nicardine  
Felbamate Verapamil  
Mephenytoin Nimodipine  
Mesuximide   
Phenobarbital   
Phensuximide   
Table 1. Drugs that may induce gingival fibromatosis (Doufexi et al., 2005) 
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Among the first two drugs’ categories, phenytoin and nifedipine are responsible for the 
most frequent forms of GF. The prevalence of GF secondary to drug treatment ranges in 
different studies, from 0 to 100% following long term phenytoin therapy, 0.5 to 83% after 
nifedipine and 8 to 81% following treatment with cyclosporin A (Kataoka et al ., 2005). The 
variability of these figures, which reflects heterogeneity of investigated cases, does not allow 
at present to suggest any empiric risk of developing an adverse reaction to these 
medications. In addition, to date, a correlation between the administered dose and the 
prevalence and severity of GF cannot be established. Nevertheless, it has been found that 
the combined regimen of nifedipine and cyclosporine in children undergoing organ 
transplants increases both the prevalence and severity of GF (Somacarrera et al., 1994). The 
development of GF after drug exposure has been related to an underlying individual genetic 
susceptibility. Possible candidate risk factors have been considered the polymorphic 
mutations in genes affecting the activity of cytochrome P450, which is responsible for the 
hepatic metabolism of drugs implicated in GF (Seymour et al., 2000). 
2.2 Hereditary gingival fibromatosis 
Hereditary gingival fibromatosis is a rare disorder (about one in 750,000 individuals), 
transmitted either as an autosomal dominant or, rarely, an autosomal recessive trait 
(Jorgenson and Cocker, 1974, Takagi et al., 1991). Different inheritance patterns, ages at 
onset and severity of the clinical manifestations in these patients, along with the presence of 
both isolated and syndromic forms reflect the underlying genetic heterogeneity. To date, 
four loci for isolated HGF have been identified, on chromosomes 2p21 (GINGF1, MIM # 
135300), 5q13-q22 (GINGF2, MIM 605544), 2p23.3-p22.3 (GINGF3, MIM 609955) and 11p15 
(GINGF4, MIM 611010). An additional locus has been assigned to chromosome 2p16-p13. 
Sequencing of the 16 known genes, which mapped...GINGF1, in the critical region of 
GINGF1 disclosed a heterozygous frameshift mutation in Son-of-Sevenless-1 (SOS-1) gene, 
which co-segregated with the disease in a Brazilian family (Hart et al., 2002). 
Emerson described in 1965, the segregation of isolated GF in a family, for 4 generations. The 
disease was transmitted to the children from an affected parent, with the exception of a 
woman who, though not affected, transmitted the disease to subsequent generations 
through affected children, down to her great-grandchildren. The only affected male did not 
have children (Emerson, 1965). The transmission of the disease through an unaffected 
woman may be related to a lack of penetrance of the mutation or to mutations of an 
imprinted gene that is expressed only if maternally transmitted.  
Linkage analysis of the entire genome in a Brazilian family with isolated, autosomal 
dominant GF, led to the identification of a locus on chromosome 2p21-p22, named GINGF1. 
Among the 32 family members identified, 12 had GF of varying severity; the youngest 
patient was 4 years old (Hart et al., 1998). Shashi et al have extended linkage analysis to 
more members of the family previously described and characterized the duplication 2p13-
p21, already observed in a child by Fryns et al. (1989). This study restricted the disease-locus 
to a region of 8 Mb on chromosome 2p21, while the chromosomal region found duplicated 
in the child, was proximal to the first, on 2p13-p16 (Fryns et al., 1989, Shashi et al., 1999). 
Genotyping of four Chinese families with the same method, localized the disease-locus in a 
region of 8.7 cM on chromosome 2p21, which overlaps with that found in the Brazilian 
family, by 3.8 cM (Xiao et al., 2000). The sequencing of the 16 known genes present in the 
candidate region, has led to the identification of a heterozygous frameshift mutation, the 
insertion of a cytosine (g.126.142-126.143insC) in the Son-Of-Sevenless gene, 1 (SOS-1). The 
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mutation causes premature termination of the protein and the formation of a chimeric 
product, that consists of 1,105 amino acids, 1,083 amino of which are preserved, towards the 
NH2-terminal, followed by 22 new ones. The premature termination eliminates four 
functional domains near the COOH- terminal, rich in proline, that are necessary for binding 
with wild type Grb2 (Hart et al., 2002). 
Wild type SOS protein consists of three functional segments: the catalytic segment, 
consisting of the Cdc25 domain and the domain of exchange with Ras (REM), a regulatory 
NH2-terminal segment that contains the histone domain, the DH domain and the PH 
domain (homologous to plecstrin) that interacts with PIP2 phosphatidic acid, and the 
COOH-terminal segment that contains binding sites for various proteins including Grb2. 
SOS1 protein acts as a guanine exchange factor (GEF), which links receptor tyrosine kinases 
to the Ras pathway and controls, therefore, cell proliferation, differentiation, vescicle 
trafficking and regulation of the cytoskeleton’s actin. Under the supervision of two classes of 
regulatory proteins, the GEF and those activating the GTPase, the Ras protein functions as a 
molecular switch in the cycle of GDP/GTP. Three Ras-GEFs have been characterized, SOS, 
the guanine nucleotide-releasing factor and the guanylate nucleotide-releasing protein. All 
three control the activity of Ras by catalyzing the release of GDP and the association with 
GTP. Two regulatory regions determine the GEF activity of SOS1: a catalytic site that 
interacts with the nucleotide-free form of Ras and an allosteric site that enhances the 
exchange activity when linked to the nucleotide-bound form of Ras. Growth factors induce a 
rapid dimerization and self-phosphorylation of their receptors. Phosphotyrosine residues in 
the catalytic region of the receptors act as binding sites for the SH2 domains of various 
proteins that function as intracellular messengers. By stimulating the growth factor, SOS is 
recruited from the cytoplasm to the cell membrane as a result of its interaction with Grb2, 
which is linked to the tyrosine residues of the phosphorylated receptor through its SH2 
domain. In this way the interaction between Grb2 and SOS causes the translocation of the 
complex to the cell membrane, where GDP is exchanged with GTP and Ras is activated. 
Although the complex Grb2-SOS1 functions exclusively as a Ras activator, SOS1 may also 
function as a GEF that is specific to the Rac1 GTPase. 
Further studies of the mechanism of Ras activation evidenced the following: after growth 
factor stimulation, SOS translocates to the cell membrane through at least two independent 
sites, the Grb2 binding site located near the COOH-terminal and the lipid-binding domain, 
PH. In addition to facilitate the anchor to the membrane, the interaction with the Grb2 
protein overcomes the negative self-regulation of SOS mediated by its COOH terminal. The 
contact of the PH domain with the membrane phospholipids induces conformational 
changes that allow the binding of Ras.GDP to the allosteric site of SOS, lowering SOS 
activity. The Ras.GTP generated during the low activity period of SOS binds to the same 
allosteric site, carrying this way SOS to its maximum activity. This model explains the 
mechanism of translocation to the cell membrane in association with the regulation of the 
catalytic activity of SOS. Moreover, the interaction of SOS with Ras.GDP or Ras.GTP further 
its position on the membrane (Gureasko et al., 2008). It has also been demontsrated that after 
stimulation with growth factor, Ras is activated both at the Golgi apparatus level and at the 
cell membrane. Activation of Ras at the cell membrane is transitory, while its action at the 
Golgi is delayed and prolonged (Buday et al., 2008). 
Jang et al showed that the total level of SOS1 transcript is lower in gingival fibroblasts of 
patients with HGF in respect to those of normal subjects, suggesting that the mutated SOS1 
transcript is significantly lower than the wild type transcript. However, the silencing of the 
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transcript using RNA interference caused a significant reduction of cell proliferation than 
the one caused by the silencing of the wild type transcript. This suggests that the increased 
proliferation of HGF fibroblasts is mainly due to the function of mutated SOS1. The authors 
also noted that the mutation in the SOS1 protein did not alter its distribution on the cell 
membrane or at the level of organelles and that the mutated SOS1 protein was capable of 
maintaining the activation of the Ras/MAPK pathway, in the absence of stimulation by 
growth factors. Therefore, this study evidenced that the HGF mutation determined the gain 
of function of SOS1, which, in this way, was implicated in the proliferation of fibroblasts 
regardless of binding with Grb2. The authors also proposed the application of RNA 
interference as a method of allele-specific depletion of the HGF mutated SOS1 as a control 
measure of gym hyperplasia (Jang et al., 2007). 
The locus 2p23.3-p22.3 (GINGF3) was identified in a Chinese family of 5 generations with 
autosomal dominant isolated GF, with onset between 2 and 6 years, around the period of 
tooth eruption. The 12 patients examined had GO that varied from mild to severe. Over 70 
genes mapped in the region identified. The direct sequencing of the GPR113 and SEL1 
genes, selected as candidates based on their functions in signal transduction and tumor 
suppression respectively, evidenced no mutations (Ye et al., 2005). 
In 2001, the analysis of a Chinese family with autosomal dominant isolated GF 
segregating through 4 generations, led to the identification of the 5q13-q22 locus 
(GINGF2). Ten of the 20 family members examined showed GF of very early onset, on 
average between 1 and 6 months of age. Forty-five genes were mapped located in the 
region identified, some with known functions in the control of cell growth or cell cycle 
(LY64, RAD17, THBS4, CETN3, GPR11, NAIP, OCLN, RASA1, EFNA5, FER). Among these 
the gene encoding the protein kinase IV, calcium/calmodulin-dependent was proposed as 
a candidate, given the presence of the phenocopy induced by calcium channel blockers 
(CAMK4, MIM 114080) (Xiao et al., 2001). 
Zhu et al observed two large Chinese families with isolated HGF. The disease occured 
only in the offspring of affected or carrier females, suggesting a defect of imprinting. The 
disease segregated, respectively, for 5 and 4 generations and manifested within the first 
year of life. Linkage analysis of the entire genome was positive for the 11p15 locus. The 
11p15 chromosomal region contains at least 14 genes that are subject to imprinting, 
divided into two groups, and is a region rich in tumor suppressor genes. The authors 
researched possible mutations or epimutations in the 14 known genes, localized within 
the region, with negative results. This study did not exclude, however, the presence of 
small interstitial deletions in the regulatory regions of the analyzed genes, not detectable 
with the techniques used or in other genes with maternal expression, localized in the 
region but unknown so far (Zhu et al., 2007). 
2.3 Leukemic gingival fibromatosis 
Gingival overgrowth is frequently associated with FAB M4 and M5 subtypes of acute 
myelogenous leukemia and, rarely, myelodysplastic syndrome (chronic myelomonocytic 
leukemia). The gingival biopsy shows diffuse tumor infiltration, subepithelial. The 
neoplastic cells appear large with pleomorphic nuclei, large nucleoli and eosinophilic 
cytoplasm. Although a risk factor for the development of lesions in cases of extramedullary 
acute myelogenous leukemia, is the presence of cytogenetic abnormalities (t(8; 21), inv16), 
there is, to date, no correlation between specific cytogenetic abnormalities and gingival 
involvement (Vural et al., 2004). 
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2.4 Differential diagnosis 
The drug-induced forms are clinical and histological phenocopies of the hereditary forms, 
which can be distinguished only based on positive family history. In addition, acquired 
forms can be recognized based on the presence of dental plaques and regression following 
elimination of the pathogenic noxa (Doufexi et al., 2005). Generalized GO may also result 
from local inflammation, pregnancy or leukemia. Although the leukemic forms resemble 
HGF, they can be differentiated based on negative family history and histological evidence 
of neoplastic infiltration. 
3. Syndromic gingival fibromatosis 
We classified GF syndromes in two large groups of known and unknown aetiology. In the 
first group, GF has been described as an occasional or constant sign of some syndromes of 
known aetiology, characterized by the fact that the causative molecular lesions affect the 
same cellular pathway.  
The second group consists of the rare reports of GF associated with a variable constellation 
of signs and symptoms that, taken together, represent the group of syndromic GF of 
unknown aetiology. The significant phenotypic overlap of these conditions is underlined by 
the presence of intermediate phenotypes that, to date, cannot be classified with certainty in 
distinct clinical entities. This clinical heterogeneity is reflected into a genetic heterogeneity, 
evidenced by the presence of observations of autosomal dominant or recessive transmission. 
The different conditions or observations are described below, based on a range of variable 
expression, which extends between the association of GF with hypertrichosis up to the 
multi-systemic syndromes of Zimmermann-Laband and Ramon. 
3.1 Definition of hypertrichosis  
Hypertrichosis is defined as the excessive growth of hair, which is distributed normally 
according to a variable spectrum, compared to the one of individuals of the same age, sex 
and ethnicity. Hypertrichosis may present with localized or generalized distribution and 
consist of immature or terminal hair. In the case of generalized hypertrichosis (GH), facial 
hair is accentuated on the frontal, temporal and preauricular regions. The eyebrows may be 
thick or confluent. On the back, hair converges along the midline, where it often forms 
whirls over the spine. The distribution can also be localized, associated with nevi or a spina 
bifida occulta, a previous trauma or irritation from chemicals and some inherited conditions 
autosomal dominant or recessive. Hypertrichosis should be distinguished from hirsutism 
that is excessive hair growth with distribution of male type (upper lip, chin, chest, linea alba, 
thighs and armpits), and that can be idiopathic or associated with overproduction of 
androgens. In contrast to hypertrichosis, the presence of hirsutism in childhood should 
orient towards the exclusion of endocrine causes of virilization. Generalized hypertrichosis 
may be one of the signs of a syndrome or of a metabolic disease (Baumeister, 1995). 
3.2 Syndromic gingival fibromatosis of known aetiology 
The syndromic forms of GF of known aetiology, include some phacomatoses, such as 
neurofibromatosis type 1, tuberous sclerosis and certain metabolic diseases such as alpha-
mannosidosis (MIM #248500), Salla disease (MIM #604369), and I cell disease (MIM 
#252500). In the case of the phacomatoses, the overgrowth is characterized by fibrotic 
changes typical of gum neurofibromas/angiofibromas. In the case of metabolic diseases, 
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histology shows the accumulation of gum-specific molecules, identical to those identified in 
other tissues (Ishigami et al., 1995, Gorlin et al., 2001). Almost all patients with Robinow 
syndrome (MIM # 268310) have gingival hyperplasia with dental crowding (Wilkie, 2008). 
The gingival hyperplasia is observed in 65% of patients with Costello syndrome 
(Hennekam, 2003) and in patients with leprechaunism or Donohue syndrome (MIM 
#246200) (Gorlin et al., 2001). Gingival hyperplasia is a constant feature of the multiple 
osteolysis syndrome of Murray-Puretic-Drescher, while it occurs occasionally in Winchester 
syndrome (MIM #277950) (Gorlin et al., 2001, Mosig et al., 2008). A single epileptic patient 
with Bardet-Biedl syndrome manifested GF, probably secondary to carbamazepine therapy 
(Drugowick et al., 2007). With the exception of the phacomatoses and Costello syndrome, 
that are due to autosomal dominant mutations, all other known disorders with GF are 
inherited as autosomal recessive traits. Sun et al. (2009) demonstrated that generalized 
hypertrichosis terminalis with or without gingival hyperplasia is a contiguous gene disorder 
caused by deletion of chromosome 17q24.2-q24.3. One of the affected individuals displayed 
a phenotype resembling Julia Pastrana (1834-1860), the first known case of GF, 
hypertrichosis, macrocephaly and coarse facies (Bondeson e Miles, 1993).  
3.2.1 Ras-MAPK pathway and gingival overgrowth 
Gingival overgrowth may be an occasional or recurrent feature in some genetic disorders 
caused by alterations in the proteins of the RAS-MAPK pathway. This pathway is regulated 
by the action of the SOS-1 protein, which is mutated in a subset of patients with isolated GF. 
Hart et al., (2007) demonstrated that the overall level of SOS-1 transcript is lower in HGF1 
fibroblasts. The relative level of wild-type SOS-1 transcript appeared to be higher than the 
mutant transcript in HGF1 fibroblasts. The targeting of mutant transcripts by methods of 
RNA interference produced more profound effects on reduction of cell proliferation than the 
targeting of the wild-type, suggesting that the increased proliferation of HGF1 fibroblasts 
was chiefly dependent upon the function of mutant SOS-1. 
Ras proteins are enzymes associated to the cell membrane that fluctuate from the active state 
of binding the active guanosine triphosphate (GTP) to the inactive state of binding with 
guanosine bisphosphate (GDP). The Ras GTPases are key mediators in pathways that 
transmit extracellular stimuli, through receptors on the cell surface, to the cell nucleus. They 
act as molecular switches in the processes of proliferation, differentiation, survival and cell 
death and are activated by different types of cellular receptors or calcium channels, 
upstream of the pathway. The exchange reaction between GDP and GTP is triggered by 
guanine nucleotide exchange factors, including the SOS-1 protein. The activated form of 
association with the GTP interacts with a broad spectrum of effector proteins including Raf, 
MEK1/2 and ERK1/2, and triggers downstream pathways (Aoki et al., 2008). 
The SOS-1 protein is expressed in various tissues and cells, including human gingiva, where 
it can be localized inside the epithelial and stromal cells. The SOS-1-Ras-ERK1/2 pathway 
seems to be the central switch of expression of key molecules of the fibrosis process and of 
HGF. In fact, the activation of this pathway increases the expression of type IV collagen, the 
connective tissue growth factor CTGF, growth factor TGF-b, of the collagenase inhibitors 
TIMP and decreases the expression of metalloprotease MMP that degrades extracellular 
matrix components. The loss of function of metalloprotease type 2, that causes Winchester 
syndrome, results, therefore, in an altered homeostasis of connective tissue with 
accumulation of its physiological substrates, including collagen, fibronectin and laminin. 
Thus, the increased activation of the Ras/MAPK pathway by mutations of the SOS-1 gene 
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that determine a permanently active form of the coded protein, result in the increase of the 
expression of all pro-fibrotic molecules mentioned above. 
Drugs that induce GF disturb the metabolic pathways involved in the translation of signals 
on behalf of the intracellular calcium ions (Ca2+). This suggests that this pathway is involved 
in the development of fibrosis. Several ion channels located on the cell membrane regulate 
the flow of Ca2+ ions, which, in turn, affects the signal transduction pathways, including the 
Ras/MAPK pathway, directly or indirectly, through proteins that bind Ca2+. Among these, 
the best characterized to date are the calmodulins (CaM) that reduce the expression of TGF- 
β and the activation of ERK1/2. 
Ras proteins also participate in the communication between the insulin-receptor complex on 
the cell surface and the activation of cytosolic proteins downstream. In particular, the 
insulin receptor interacts with the proteins Gab-1, p60dok, Cbl, APS and isoforms of Shc10. 
The phosphorylated tyrosine residues of the activated insulin receptor act as docking sites 
for proteins containing SH2 domains (Src-homology-2). Many of these molecules are 
"adaptors", including proteins PI(3)K and Grb2, which, in turn, bind to the guanine 
nucleotide exchange factors, including the SOS protein-1 and activate the Ras/MAPK 
pathway (Saltiel and Kahn, 2001). However, it is not known whether insulin receptors are 
expressed in gingival tissue. 
In conclusion, the SOS-1-Ras-ERK1/2 pathway regulates genes whose expression is altered 
in HGF and are involved in the process of fibrosis. It might be suggested that a defect at any 
level of this signaling cascade, which increases the expression of pro-fibrotic genes, 
promotes the development of GF. 
It is interesting to observe a gingival phenotype both in NF1, which is caused by loss of 
function of neurofibromin, a negative regulator of Ras activation, and in Costello syndrome, 
caused by gain of function mutations of the H-Ras gene. Although the biochemical functions 
of tuberin and hamartin are not known to date, coded respectively by the TSC1 and TSC2 
genes, we know that tuberin contains a region of homology with proteins that activate small 
GTPases such as Ras protein. The loss of function of tuberin could lead to a continuous 
stimulation of the pathways triggered by Ras. The CMG2 protein, mutated in the Murray-
Puretic-Drescher syndrome, which is consistently associated with gingival hyperplasia, is an 
integrin-like molecule of the cell membrane that regulates cell adhesion to laminin and to 
collagen type IV. The metabolic pathways regulated by CMG2 are not known in detail, to 
date, but it is known that the cell adhesion pathway transmits signals to SOS-1-Ras-ERK1/2 
and therefore there is a possible link between CMG2 and this signaling cascade. The 
differential involvement of multiple tissues or of the gingiva exclusively seems to depend on 
the functional importance of each of the mutated genes in the different cells and tissues 
(Häkkinen and Csiszar, 2007). 
Several heterozygous, gain of function mutations of the SOS-1 gene have been associated 
with a distinct form of Noonan syndrome with high prevalence of ptosis and pulmonary 
valve stenosis, ectodermal symptoms and, generally, the absence of mental and 
developmental retardation. None of the affected with confirmed SOS-1 mutations described 
to date, presented with GF or was predisposed to the development of tumors. Furthermore, 
the mutations described are not associated with any type of tumor (Tartaglia et al., 2007, 
Roberts et al., 2007, Zenker et al., 2007). There were no further observations of HGF due to 
SOS-1 mutations. The C.3248-3249insC mutation in exon 21 of the gene, linked to HGF, has 
not been observed to date in people with Noonan syndrome. All SOS-1 mutations result in a 
gain of function but the one related to HGF is the only frameshift one, resulting in a 
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chimeric, truncated protein. All other SOS-1 mutations described to date do not result in 
truncated proteins. The HGF mutation affects the SOS-1 domain of binding to Grb2 
correlated to its self-negative regulation, but functional studies have shown that this 
mutation does not alter the intracellular localization of SOS-1 or its function of activating the 
Ras/MAPK pathway via ERK1/2 (Jang et al., 2007). 
Mutations in key components of the MAPK pathway that cause prolonged activation of ERK 
are related to the formation of tumors (Aoki et al., 2005). The formation of skin tumors has 
been highlighted in transgenic mice for SOS-1, artificially constructed, with deletion of the 
COOH terminal (Sibilia et al., 2000). It is believed that the activity of the strong promoters 
used in these experiments produces high levels of expression of the mutant protein that 
causes significant increase of ERK activity and leads to transformation. This means, there is 
probably a threshold of protein expression beyond which transformation happens. It is 
assumed that the benign form of the overgrowth in HGF can be interpreted as follows: the 
low levels of mutant SOS-1 that is partially free from self-inhibition could lead to a 
continuous activation of ERK that could be sufficient to cause increased proliferation but not 
cell transformation (Jang et al., 2007). In the presence of a cellular environment with EGFR 
receptor of reduced activity, transgenic mice do not form skin cancers, despite the gain of 
function, and thus the continued activation of the MAPK on behalf of the artificial SOS-1 
protein (Sibilia et al., 2000). 
In conclusion, it is not yet known why the various SOS-1 mutations produce distinct 
phenotypes or why the overgrowth in HGF is confined in the gingival tissue. A specific 
mutation-disease correlation could be hypothesized, secondary to the specific functions of 
the SOS-1 protein in gingival tissue or a tolerance/compensation of the gain of function 
caused by the frameshift mutation, in the other tissues (Jang et al., 2007). 
3.3 Syndromic gingival fibromatosis of unknown aetiology 
A number of subjects with GF associated with variable signs and symptoms can be regarded 
as examples of GF syndromes of unknown etiology, which, in descending order of number 
of observations, include GF, hypertrichosis, epilepsy and/or mental retardation (MR) 
syndrome; Zimmermann-Laband syndrome (MIM %135500); Jones syndrome (Jones et al., 
1997); Ramon syndrome (MIM 2662700); Rutherfurd syndrome (MIM %180900), GF 
syndrome and characteristic facies (MIM 228560). GO is an occasional feature of Sturge-
Weber syndrome (MIM 185300). This anomaly is secondary to angiomatous proliferation, 
worsened by GF caused by treatment of the epileptic symptoms (Bhansali et al., 2008). In 
general, these cases are rare and mostly sporadic, with the exception of Ramon syndrome, 
an autosomal recessive disorder, and single reports of affected sibs pairs, born to unaffected 
parents, presenting with GF, hypertrichosis, epilepsy and/or MR or manifesting the 
Zimmermann-Laband syndrome or intermediate phenotypes (Gorlin et al., 2001). 
Taking into account the GF syndromic forms of unknown aetiology mentioned above, the 
existence in the literature of not clearly distinct phenotypes becomes evident, given the 
rarity of the observations and the significant overlap of signs/symptoms. There are 
“wide” clinical spectrums such as Ramon and ZL syndromes, which include a set of 
signs/symptoms that have also been observed individually associated with GF. The 
constant segregation of the association of GF with acro-osteolysis or cherubism, all three 
very rare signs, suggests that the ZL and Ramon syndromes are distinct clinical genetic 
entities. The two syndromes share, with different frequencies, the observations of GF, 
hypertrichosis, epilepsy and MR, an association described as an isolated clinical entity, 
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and retinal alterations of the pigmentosum type (Koch et al., 1992, Parkin and Law, 2001). 
It has been suggested that the association of isolated GF with hypertrichosis is the 
minimum clinical expression of the phenotypic spectrum of the ZLS (Lacombe et al., 1994) 
but that should probably be differentiated, given the absence of any further 
signs/symptoms (Robertson et al., 1998). An important hallmark is the finger hypoplasia, 
especially of the feet, and/or of the nails with or without an underlying hypoplasia of the 
terminal phalanges, especially in a patient without cognitive impairment and/or 
organomegaly, both non-mandatory symptoms of the ZLS. Based on the observation of 
the association of this last sign to GF and a hyperextensibility of the small joints Bakaeen 
and Scully (1991) reported the recurrence of the syndrome of ZL, in the children of a 
couple of cousins. 
The unclear distinction between the phenotype of ZL and GF, hypertrichosis, epilepsy, 
MR, has been highlighted by several observations of intermediate phenotypes. Vontobel 
et al (1973) described a sporadic patient, who presented GF, congenital generalized 
hypertrichosis, mild hypoplasia of the fingernails and, especially, the feet, and 
acromegaloid features acromegaloidi that were not due to an underlying endocrinological 
disorder. The patient had psychomotor retardation (she walked alone at the age of 2 
years, spoke the first phrases at 3-4 years), but her IQ was normal. Göhlich-Ratman et al 
(2000) observed the recurrence, in two sisters, daughters of first cousins, of coarse facies, 
profound MR with severe language impairment, early onset gingival hyperplasia, 
hypertrichosis and generalized tonic-clonic seizures with onset at 2 years of age. Both also 
had brachydactyly type E with bilateral shortness of metacarpals III-V and 
brachitelephalangy of the first finger, hypoplastic toenails, and bilateral sandal gap. The 
authors rule out ZLS for the lack of open bite and hepatomegaly, signs, however, that are 
not present in all patients with ZL reported in the literature. They speculate, however, 
that this is a broader phenotype than that observed by Anavi et al (1989) or a distinct 
syndrome of autosomal recessive GF. 
However, the assumption that all these clinical features are part of the same phenotypic 
spectrum seems validated by the observation of segregation of distinct phenotypes from a 
father to his two sons. The father, at the age of 45, presented with GF, hypertrichosis, 
hearing loss and hypotelephalangism with brachydactyly and nail hypoplasia of the 
thumbs. His 13-year-old son had the same clinical picture, along with hypertrichosis, in the 
absence of MR. A second son, of 10 months, had inherited the paternal GF and defects of the 
fingers. The mother and the only daughter were not affected (Haytac and Ozcelik, 2007). 
Gingival overgrowth variably associated with GH, MR or epilepsy has been described as a 
distinct, isolated disorder, with an autosomal dominant inheritance pattern (Anderson et al., 
1969, Horning et al., 1985, Cuestas-Carnero and Bornancini, 1988), or as a manifestation of 
more complex disorders similar to ZLS (Gorlin et al., 2001). It was suggested that the 
association of GO, GH, MR or epilepsy could represent the mildest expression of ZLS. 
Distinguishing features in the former include absence of additional features, in particular 
nail hypoplasia with or without hypotelephalangism, mostly affecting the hands (Lacombe 
et al., 1994, Robertson et al., 1998). Clinical variability between patients with GO, GH, MR or 
epilepsy likely reflects genetic heterogeneity is also supported by different inheritance 
patterns (Nevin et al., 1971, Bakaeen and Scully, 1991, Haytac and Ozcelik, 2007). All these 
disorders can be lumped in a continuum of increasing severity, from the mildest phenotypes 
displaying GO, GH, MR and epilepsy to the most complex disorders reported by Göhlich-
Ratman et al (2000) and Ramon et al (1967). 
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4. Generalized hypetrichosis, tonic-clonic seizures with onset in the first 
months of life, severe mental retardation and gingival overgrowth unrelated 
to the antiepileptic treatment 
We had the opportunity to evaluate an 8-year old girl that was referred for genetic 
counselling because of MR and convulsions. She was the first daughter of healthy non-
consanguineous Italian parents. A younger sister was clinically normal. At birth, the mother 
was 24-years-old and the father 29. Family history was unremarkable. Pregnancy was 
complicated by threatened miscarriage during the first trimester, for which the mother 
was advised with bed rest and treated with isoxuprine. No exposure to teratogenic agents 
was reported. Serologic tests for cytomegalovirus, toxoplasmosis and rubella, and triple 
serum marker screening were negative. A standard ultrasound scan at 22½ weeks of 
gestation was normal. The patient was born at 36 weeks of gestation with the use of 
forceps. Birth weight was 3,130 g (50th percentile), length 47 cm (10th percentile) and OFC 
34 cm (25th percentile). She presented with delayed after birth cry and there was, 
transitory, self-resolving cyanosis, obvious generalised hypertrichosis and jaundice, 
which was treated with phototherapy. Apgar scores were not recorded. Cord blood gas 
values were normal, no resuscitation was required and paediatric monitoring did not 
reveal any end-organ dysfunction. The patient developed tremors from the first days of 
life, that, by age of 2 years turned into recalcitrant, generalized, tonic-clonic seizures. The 
episodes were initially unsuccessfully treated with phenobarbital that was substituted 
with sodium valproate. Treatment with sodium valproate easily controlled the seizures 
but this was changed to topiramate after 14 months because the patient was frequently 
observed lethargic. Developmental milestones were delayed: she sat at 9 months and 
walked at 2 years. At the time of the evaluation she was undergoing psychomotricity 
since the last 6 years. 
On physical examination she had presented excessive growth of apparently terminal hair, 
distributed over the upper lip, cheeks, back, arms and forearms and legs. The hair on the 
back converged over the midline, forming whorls over the lower spine. The face and hands 
were otherwise unremarkable. Oral inspection disclosed a grade III GO, covering at least 
threequarters of the tooth crowns (Bökenkamp et al., 1993). Enlarged gingiva was normal in 
colour and felt firm on palpation. The patient was mentally retarded and had not acquired 
yet any language skills. She was 120 cm tall and weighed 21 kg (both on the 3rd percentile). 
On clinical evaluation, the parents were normal. 
Electroencephalography disclosed bilateral parossistic activity over the frontal and temporal 
regions, with a right-side prevalence. Brain computed tomography and magnetic resonance 
imaging, spine radiographs, heart and abdominal ultrasound were unremarkable. Auditory 
brainstem response test and ophthalmologic evaluation were normal. The effect of 
anticonvulsant therapy was monitored with computerized bone mineralometry, which 
showed unremarkable results. Blood levels of total and free testosterone and DHEA-S were 
normal. Metabolic workout including serum lactate, ammonia, amino acids, organic acids, 
cholesterol, very long chain fatty acids, lysosomal enzymes, transferrin isoelectric focusing 
and urinary mucopolisaccarides was normal. Fibroblast chromosome analysis at the 550 
bands level and aCGH analysis at 125 kb of resolution yielded normal results. Parents did 
not give their permission to perform gum biopsy. 
This latter patient presented with a unique association of GH, tonic-clonic seizures with 
onset in the first months of life, severe MR and GO unrelated to antiepileptic treatment, in 
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the absence of other signs and/or symptoms (Douzgou et al., 2009). The clinical features of 
this patient overlapped in part those found in cases of GO associated with GH, MR, epilepsy 
and ZLS or related phenotypes (Araiche and Brode, 1959, Nevin et al., 1971, Vontobel et al., 
1973, Bakaeen and Scully, 1991, Haytac and Ozcelik, 2007). Tonic-clonic seizures have been 
reported so far only in a single patient with ZLS, who did not manifest GH (Chodirker et al., 
1986). Two patients with the GH of Cantu syndrome (CS) presented with GO but manifested 
additional features and had no seizure (Rosser et al., 1989). Following the original 
observation of Anavi et al (1989), concerning a brother-sister pair born to consanguineous 
parents, two additional patients have been reported with similar clinical characteristics, 
including central nervous system (CNS) anomalies and neurological features (Snyder, 1965, 
Kiss, 1990). CNS anomalies were not found in our patient, arguing for a different origin of 
her neurological manifestations. Our patient also resembled Snyder’s case 2, but absence of 
ataxia appeared as the major distinguishing criteria.  
ZLS and Ramon syndrome are considered separate disorders, characterized by the 
association of GO with hypotelephalangism or cherubism. GH, MR, epilepsy and retinal 
changes can be overlapping features (Gorlin et al., 2001, Koch et al, 2002). It seems that these 
two diseases represent the extreme spectrum of the phenotypes exhibiting GO, GH, MR and 
epilepsy. All these disorders can be lumped in a continuum of increasing severity, from the 
mildest phenotypes displaying GO, GH, MR and epilepsy to the most complex disorders 
reported by Göhlich-Ratman et al (2000) and Ramon et al (1967). The unique phenotype of 
our patient, displaying GO, GH, MR and epilepsy without other signs and/or symptoms 
overlaps, in part, with the features observed in the three autosomal recessive disorders 
sharing GO, GH, MR and epilepsy and seems to represent a further example of clinical 
variability within the occurring in GO plus conditions (Table 2). 
4.1 Genetic counselling of gingival fibromatosis 
The genetic counselling of a person with GF begins with the collection of anamnestic data 
such as exposure to GF-inducing drugs, the presence of systemic conditions (pregnancy, 
leukemia), other family members affected, presence of psychomotor retardation and/or 
seizures. Physical examination can evaluate a number of signs/symptoms that may orient 
towards the definition of the recurrence risk (RR). In the absence of other signs/symptoms 
associated, the SOS-1 gene can be sequenced. In case the molecular analysis is negative, a 
linkage analysis of the GINGF2-4 known loci, to date, can be undertaken. The presence of 
hearing loss (Jones syndrome) or corneal opacities (Rutherfurd syndrome) or the association 
with hypertrichosis suggest an autosomal dominant segregation. The presence of cherubism 
confirms the diagnosis of Ramon syndrome, which is autosomal recessive. The finding of 
macrocephaly orients towards the clinical entities described by Canun et al. (2003) and 
Goldblatt and Singer (1992), with different modes of transmission, depending on the 
associated dysmorphisms. The recognition of a pattern of multisystemic anomalies (heart 
disease and/or short stature and/or genitourinary anomalies) associated to GF and 
hypertrichosis may point to specific, rare syndromes of defined RR. The nail hypoplasia 
with or without hypotelephalangism allows the diagnosis of ZL, but does not define the RR. 
Regarding possible patients with the combination of variable GF, hypertrichosis, epilepsy 
and MR, cerebral magnetic resonance imaging and X-rays of hands and/or a 
metacarpophalangeal profile may confirm a 25% RR in the cases, respectively, of CNS 
anomalies or brachydactyly/metacarpy (Figure 1). 
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1, Horning et al. (1985); 2, Anderson et al. (1969); 3, Cuestas-Carnero and Bornancini (1988); 4, Araiche 
and Brode (1959); 5, Nevin et al. (1971); 6, Vontobel et al. (1973); 7, Bakaeen and Scully (1991); 8, Haytac 
and Oczelik (2007); 9, Gorlin et al. (2001); 10, Rosser (1998); 11, Snyder (1965); 12, Anavi et al. (1989); 13, 
Kiss (1990); 14, Göhlich-Ratman et al. (2000); +, present; - absent; +/-, variable; GO, gingival 
overgrowth; GH generalized hypertrichosis; MR, mental retardation; y, years; RS, Ramon syndrome; 
ZLS, Zimmermann-Laband syndrome; CS, Cantu syndrome; P2, patient 2; BDE, brachydactyly type E; 
CNS, central nervous system; At, ataxia; BA, brain atrophy; SP, spastic paraparesis; Hp, hypotonia; AR, 
autosomal recessive; AD, dominant. 
Table 2. Clinical features in patients with GF syndromic disorders. 
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Fig. 1. HGF genetic counselling algorithm; blue arrows, presence; red arrows, absence.  
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The prognosis of patients with syndromic GF is related to the presence of MR, postnatal 
growth failure, epilepsy, heart disease and predisposition to cancer. In the specific patient 
that we described, given a possible diagnosis of ZLS, the monitoring of cardiorespiratory 
function before the age of 18 years or before embarking on exercise programs is suggested. 
5. Conclusion  
The patient that we observed is an example of an extremely rare developmental defect 
present at birth, which is not obvious to the methods currently used for prenatal diagnosis. 
Her condition is part of the 2-3% of congenital dysmorphisms that require genetic 
counselling. The absence of a known genetic lesion narrows the diagnostic approach to the 
clinical-observational aspect. The comparison and classification of this very rare clinical 
observation was essential in defining the risk of recurrence of the family and the patient's 
prognosis. The clinical classification of rare genetic conditions is an essential step, along 
with the descriptions of additional observations and the advances in research, for the 
discovery of their molecular causes, and thus for the care of the patients and their families. 
Of all the branches of medical genetics, genetic counselling of rare congenital dysmorphisms 
represents the field with the greatest impact of the clinical geneticist. This is justified by such 
an association of factors as the high incidence of birth defects and hence the increased 
demand of services of genetic counselling and the rarity of the individual observations, 
which does not, therefore, permit the diagnosis in first level health services and/or by staff 
with a general training in medical genetics. The organization of the clinical genetics service 
in a second or third level facility allows the grouping of these observations in registers or 
databases that permits the comparison of clinical pictures among different patients as well 
as the exchange of opinions with other experts. All these processes depict the clinical 
geneticist as the central, decision-making figure of the genetic counselling of patients with 
rare dysmorphisms. 
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